American Society of Clinical Oncology (ASCO) Bibliometric Report

Introduction

This report provides a comprehensive analytics report of the publisher American Society of Clinical Oncology (ASCO) including basic bibliometric information, citation data, impact metrics, top journals, publication keywords, etc., over recent years. The Crossref database (up to the end of 2021) processed by ScienceGate has been used for this report as the source of data.

American Society of Clinical Oncology (ASCO) has published 141283 documents so far, receiving a total of 2421860 citations. These numbers are equal to 0.12% and 0.22% of the total documents and citations in the scientific community, respectively. American Society of Clinical Oncology (ASCO) has a score of 17.14 as a number of citations per document based on all recorded data. There are different types of documents published by American Society of Clinical Oncology (ASCO). In this regard, Journal Article, Dataset, and Other a with the total document number of 140240, 1042, and 1 have the largest share, respectively. These numbers are equal to 99.26%, 0.74%, and 0.00% of the total documents published in American Society of Clinical Oncology (ASCO) so far, respectively. American Society of Clinical Oncology (ASCO) has been an active publisher from 1983-2021.

Basic Bibliometric Information

This section provides the bibliometrics data of American Society of Clinical Oncology (ASCO) over the last 11 years, including the number of published documents, total citations, citations per document, and scaled number of citations per document by year. Share of American Society of Clinical Oncology (ASCO) documents and citations among all published scientific documents are also presented here. American Society of Clinical Oncology (ASCO) has the highest annual number of publications in 2018, with 10006 published documents. Most annual citations are also received in 2010, with 132148 citations. The highest citations per document’s scores, scaled by the number of years ahead, are associated with 2020, with scores of 0.73.

YearDocumentsCitationsCitations/DocumentsAverage Citations/DocumentsDocuments ShareCitations Share
2010605013214821.84261.98570.00170.0032
2011705710675715.12781.51280.00180.0026
201277369026211.66781.29640.00190.0023
201374648277411.08981.38620.00170.0022
20147841653258.33121.19020.00170.0019
20157814683768.75041.45840.00160.0022
20168563557336.50861.30170.00160.0020
20178634471745.46371.36590.00150.0021
201810006353673.53461.17820.00170.0021
20198764177102.02081.01040.00140.0018
2020924467340.72850.72850.00130.0020

Document Types

There are different types of documents published by publishers. In this section, the yearly publication data of American Society of Clinical Oncology (ASCO) are presented by document type, including Journal Articles, and Datasets.

The number of published documents by American Society of Clinical Oncology (ASCO) are 140240, and 1042 for Journal Articles, and Datasets, respectively. These numbers are equal to 0.15%, and 0.05% of the whole published Journal Articles, and Datasets in the database so far, respectively.

The number of received citations by Journal Articles, and Datasets of American Society of Clinical Oncology (ASCO) are 2421857, and 3, respectively. These numbers are equal to 0.23%, and 0.00% of the citations received by whole Journal Articles, and Datasets of the database so far, respectively.

The h-index value for published Journal Articles, and Datasets by American Society of Clinical Oncology (ASCO) are 513, and 1, respectively. The corresponding values for the whole data of the database are 3201, and 98, respectively.

The g-index value for published Journal Articles, and Datasets by American Society of Clinical Oncology (ASCO) are 40, and 1, respectively. The corresponding values for the whole data of the database are 129, and 20, respectively.

The score of citations per document for published Journal Articles, and Datasets by American Society of Clinical Oncology (ASCO) are 17.269, and 0.003, respectively. The corresponding values for the whole data of the database are 11.521, and 0.070, respectively.

The highest number of annually published Journal Articles, and Datasets by American Society of Clinical Oncology (ASCO) are 9993, and 328, respectively. The corresponding year of maximum publication for Journal Articles, and Datasets are 2018, and 2019, respectively.

The highest number of annual received citations by Journal Articles, and Datasets published in American Society of Clinical Oncology (ASCO) are 132148, and 3, respectively. The corresponding years of maximum received citations for Journal Articles, and Datasets are 2010, and 2019, respectively.

The highest values of citations per number of document for Journal Articles, and Datasets published in American Society of Clinical Oncology (ASCO) are 21.84, and 0.01, respectively. The corresponding years of maximum values of citations per document for Journal Articles, and Datasets are 2010, and 2019, respectively.

Impact Metrics

Various metrics and indicators are used to evaluate the impact and quality of publishers and journals. Here, h-index, g-index, and i-index are selected as impact evaluation metrics of the publisher American Society of Clinical Oncology (ASCO).

H-index

H-index indicates the number of articles published by a journal/publisher, h, that have been cited at least h times. h5-index and h10-index are the h-index for papers of a publishers/journals published in the last 5 and 10 years, respectively. h-index, h10-index, and h5-index of the documents published by American Society of Clinical Oncology (ASCO), are 513, 285, and 150, respectively. The corresponding values for the whole data of the database are 3269, 1489, and 795, respectively.

MetricAmerican Society of Clinical Oncology (ASCO)All Publishers
h-index5133269
h10-index2851489
h5-index150795

G-index

The g-index indicator is the first g papers of a publisher/journal (sorted by the highest to the lowest number of citations) that have cumulatively received at least g^2 citations. Again, g5-index and g10-index are the g-index for papers of a publishers/journals published in the last 5 and 10 years, respectively. G-index, g10-index, and g5-index of the documents published by American Society of Clinical Oncology (ASCO) are 40, 28, and 20, respectively. The corresponding values for the whole data of the database are 131, 80, and 55, respectively.

MetricAmerican Society of Clinical Oncology (ASCO)All Publishers
g-index40131
g10-index2880
g5-index2055

I-n index

I-n index shows the number of publications of a publisher/journal with at least n citations. Read another post here for more detailed information on different research impact metrics. It is to be noted that, i10-index, i25-index, i50-index, i100-index, i250-index, i500-index, i1000-index, i2500-index, i5000-index, and i10000-index of the documents published by American Society of Clinical Oncology (ASCO), are 22323, 16062, 11708, 6922, 2029, 545, 120, 6, 0, and 0, respectively. The corresponding values for the whole data of the database are 21796896, 10617845, 4822066, 1785083, 390499, 114230, 31648, 5505, 1423, and 355, respectively.

MetricAmerican Society of Clinical Oncology (ASCO)All Publishers
i10-index2232321796896
i25-index1606210617845
i50-index117084822066
i100-index69221785083
i250-index2029390499
i500-index545114230
i1000-index12031648
i2500-index65505
i5000-index01423
i10000-index0355

Top Journals

This section provides the basic bibliometrics data of the American Society of Clinical Oncology (ASCO) top journals, including the number of published documents, total citations, and citations per document. Share of documents and citations of each journal among all published documents by American Society of Clinical Oncology (ASCO) is also presented here. In the following tag cloud chart, top journals are displayed based on the largest number of published documents.

The Top 5 journals of American Society of Clinical Oncology (ASCO) based on the number of published documents are Journal of Clinical Oncology, Journal of Oncology Practice, Journal of Global Oncology, American Society of Clinical Oncology Educational Book, and JCO Precision Oncology. The numbers of documents published so far by these top 5 journals are 131740, 2838, 1773, 1327, and 807, respectively. These numbers are equal to 93.245%, 2.009%, 1.255%, 0.939%, and 0.571% of the total documents published by American Society of Clinical Oncology (ASCO) so far, respectively.

Concerning the number of received citations, the top 5 journals of American Society of Clinical Oncology (ASCO) are Journal of Clinical Oncology, Journal of Oncology Practice, American Society of Clinical Oncology Educational Book, JCO Precision Oncology, and Journal of Global Oncology. The total number of citations received so far by these top 5 journals are 131740, 2838, 1327, 807, and 1773, respectively. These numbers are equal to 5.440%, 0.117%, 0.055%, 0.033%, and 0.073% of the total citations received by American Society of Clinical Oncology (ASCO) publications so far, respectively.

Regarding the number of citations received per document, the top 5 journals of American Society of Clinical Oncology (ASCO) are Journal of Clinical Oncology, Journal of Oncology Practice, American Society of Clinical Oncology Educational Book, JCO Precision Oncology, and JCO Clinical Cancer Informatics. The numbers of citations received per published document so far by these top 5 journals are 18.112, 7.866, 5.938, 2.466, and 2.218, respectively.

Journal TitleDocumentsDocuments ShareCitationsCitations ShareCitations/DocumentsActive Years
Journal of Clinical Oncology1317400.932523861180.985218.11231983-2020
Journal of Oncology Practice28380.0201223230.00927.86582005-2019
Journal of Global Oncology17730.012518630.00081.05082015-2019
American Society of Clinical Oncology Educational Book13270.009478800.00335.93822012-2020
JCO Precision Oncology8070.005719900.00082.46592017-2020
JCO Oncology Practice8070.00573420.00010.42382020-2020
JCO Global Oncology4800.00343030.00010.63122020-2020
JCO Clinical Cancer Informatics4680.003310380.00042.21792017-2020

Top Keywords

The Most used keywords are of particular importance for reviewing a publisher. This section provides detailed information about basic bibliometrics data of top used keywords in American Society of Clinical Oncology (ASCO). The metrics used here are the number of documents, citations and citations per document. Share of documents and citations of each keyword among whole published documents is also presented here. In the following tag cloud chart, top keywords are displayed based on the largest number of published documents.

According to the number of published documents, the top 10 keywords of the publisher American Society of Clinical Oncology (ASCO) are breast cancer, overall survival, lung cancer, phase ii, clinical trial, cancer patients, prostate cancer, clinical trial information, colorectal cancer, and small cell lung cancer, respectively. The number of published documents in which the mentioned 10 keywords are used are, 18228, 13305, 10514, 9632, 8830, 8250, 8226, 7834, 7465, and 6516, respectively.

Based on the number of received citations, the top 10 keywords of the publisher American Society of Clinical Oncology (ASCO) are overall survival, breast cancer, lung cancer, phase ii, small cell lung cancer, disease free, cell lung cancer, small cell lung, phase iii, and quality of life, respectively. The number of citations received by the documents in which the mentioned 10 keywords are used are, 13305, 18228, 10514, 9632, 6516, 3443, 5922, 5615, 3383, and 4314, respectively.

Concerning the score of received citations per document, the top 10 keywords of the publisher American Society of Clinical Oncology (ASCO) are epidermal growth factor receptor, median survival, growth factor, response rate, high dose, disease free, prognostic factors, free survival, phase iii, and bone marrow, respectively. The score of citations received per document in which the mentioned 10 keywords are used are, 69.643, 59.223, 55.281, 47.694, 45.588, 44.392, 44.136, 42.638, 42.214, and 41.667, respectively.

KeywordDocumentsDocuments ShareCitationsCitations ShareCitations/DocumentsActive YearsActive Years For All Data
breast cancer182280.06153916820.091021.48791983-20201880-2020
overall survival133050.30344072140.620030.60611983-20201960-2020
lung cancer105140.06592054070.102119.53651983-20201921-2020
phase ii96320.22461911030.300819.84041983-20201900-2020
clinical trial88300.1141949910.094310.75781983-20201926-2020
cancer patients82500.0750955760.082611.58501983-20201884-2020
prostate cancer82260.0623953780.050611.59471983-20201905-2020
clinical trial information78340.9891265900.98743.39422004-20201991-2020
colorectal cancer74650.07731329220.094517.80601983-20201905-2020
small cell lung cancer65160.08831590000.157124.40151983-20201969-2020
phase i63260.19421015980.217016.06041983-20201909-2020
cell lung cancer59220.07941503280.146125.38471983-20201962-2020
small cell lung56150.07391462570.138726.04761983-20201969-2020
small cell52620.06581172860.113822.28921983-20201875-2020
cell carcinoma46920.0379820250.058317.48191983-20201910-2020
clinical trials44900.05961221380.111527.20221983-20201912-2020
quality of life43140.02581391870.074832.26401983-20201905-2020
high risk42990.0431930020.083921.63341983-20201930-2020
first line41270.1476764350.269818.52071985-20201711-2020
adverse events36120.1058886470.236524.54241987-20201970-2020
the impact36060.0081585350.016616.23271984-20201868-2020
disease free34430.24771528400.593344.39151983-20201901-2020
phase iii33830.19531428100.383142.21401983-20201937-2020
free survival31610.17551347800.509442.63841983-20201965-2020
phase ii study31130.2267435070.218813.97591983-20201969-2020
ovarian cancer30940.0588607190.082719.62481983-20201895-2020
grade 330430.3889786770.724025.85511985-20201944-2020
solid tumors30040.2027437970.175414.57961983-20201882-2020
locally advanced29600.1215440360.180614.87701983-20201957-2020
renal cell carcinoma28690.0797462570.102216.12301984-20201952-2020
radiation therapy28560.05741047240.162136.66811983-20201922-2020
gastric cancer28390.0511262600.04129.24971984-20201884-2020
pancreatic cancer28360.0675309290.053110.90591983-20201906-2020
metastatic breast cancer26100.1664620520.293423.77471983-20201955-2020
the mean25240.0172426470.028716.89661983-20201669-2020
growth factor25090.01771387010.034155.28141989-20201921-2020
multivariate analysis25050.0922764760.208130.52931983-20201939-2020
lymph node24820.0483534390.078721.53061983-20201908-2020
metastatic colorectal cancer24080.2336528980.321621.96761984-20201975-2020
adjuvant chemotherapy23530.1996584610.320224.84531983-20201961-2020
head and neck23390.0342461980.056819.75121983-20201781-2020
renal cell23360.0602429610.084418.39081984-20201952-2020
prognostic factors22860.09051008940.212744.13561983-20201916-2020
phase ii trial22340.2390353660.247915.83081983-20201975-2020
significant difference22270.0276434220.119219.49801983-20201923-2020
first line treatment21930.1963547880.393924.98311984-20201969-2020
response rate21850.19331042110.580547.69381983-20201949-2020
squamous cell carcinoma21510.0342342800.052015.93681983-20201910-2020
metastatic breast20670.1344482590.236523.34741983-20201955-2020
gene expression20490.0111333040.008116.25381990-20201900-2020
risk factors20170.0098558220.020027.67581983-20201948-2020
squamous cell19950.0282319720.040316.02611983-20201910-2020
t cell19810.0146384540.011219.41141983-20201953-2020
breast cancer patients18580.0729232110.090912.49251986-20201951-2020
bone marrow18420.0179767500.037741.66671983-20201882-2020
stem cell18200.0156545780.026729.98791983-20201929-2020
colon cancer17750.0561338270.067019.05751984-20201934-2020
partial response17710.3639604910.667634.15641983-20201943-2020
high dose17590.0433801890.130945.58781983-20201936-2020
multiple myeloma17570.0445391520.072922.28341983-20201898-2020
log rank test17390.3230322420.702218.54051985-20201970-2020
hepatocellular carcinoma17120.0215197460.016511.53391984-20201961-2020
line treatment17090.1596249490.218414.59861988-20201948-2020
neoadjuvant chemotherapy17010.1296277400.211116.30811984-20201969-2020
in vitro16910.0033258780.003015.30341983-20201500-2020
disease progression16680.0863478290.153728.67451984-20201948-2020
cancer care16620.1784170970.241010.28701991-20201955-2020
health care16600.0092221980.016613.37231986-20201906-2020
line chemotherapy16250.3390247540.462415.23321985-20201976-2020
logistic regression15930.0326189890.053311.92031983-20201969-2020
dose escalation15520.2157208280.202413.42011985-20201970-2020
increased risk15430.0346486930.086631.55741985-20201950-2020
stage iii15280.1786313860.290820.54061983-20201894-2020
palliative care14720.0459154320.069010.48371995-20201956-2020
median survival14680.3374869400.647159.22341983-20201954-2020
early stage14610.0427310630.086021.26151988-20201827-2020
second line14520.1519162350.203311.18111987-20201810-2020
clinical practice14290.0216365290.046325.56261986-20201905-2020
newly diagnosed14220.0685333980.135723.48661983-20201966-2020
over time14200.0164312500.037222.00701985-20201904-2020
phase i study14130.2287157940.187011.17761983-20201963-2020
generation sequencing14110.064253900.02353.82002010-20202000-2020
cancer survivors14090.0894261690.133818.57271990-20201956-2020
rectal cancer14080.0646269910.088519.16971989-20201888-2020
monoclonal antibody13960.0380489680.057035.07741983-20201500-2020
decision making13870.0074235880.015217.00651984-20201900-2020
united states13870.0043415620.013329.96541984-20201785-2020
side effects13760.0324312350.073622.69991983-20201892-2020
t cells13610.0136188830.006613.87441983-20201960-2020
epidermal growth factor receptor13590.0846946450.203869.64311992-20201970-2020
b cell13490.0215461170.037534.18611983-20201931-2020
patient reported13470.0608186040.113613.81141991-20201903-2020
bladder cancer13350.0407158430.041711.86741984-20201935-2020
median time13100.2229304810.504923.26791983-20201969-2020
real world12980.02166930.00230.53392006-20201863-2020
tumor cells12820.0381200040.032315.60371983-20201907-2020

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Related Post

Leave a Reply

Your email address will not be published.